Clinical trials: Diabetic Peripheral Neuropathic Pain
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
This is a 2-part study. In Part 1 of the study, subjects will undergo a pain reporting training program in which a painful stimulus will be applied to the subject's hand, and the subjects will be asked to report how painful the…
- Trial name
- NCT01928381
- Testing
- AZD5213 + pregabalin, pregabalin capsules
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN)
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT00407511
- Testing
- Pregabalin
- Where
- 11 sites in Colombia, Ecuador and 3 more
- Volunteers
- 121 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Neuropathies
A Long-term Study for the Treatment of Painful Diabetic Neuropathy
The purpose of the study is to investigate safety and efficacy of duloxetine for patients with painful diabetic neuropathy at long-term use.
- Trial name
- NCT00641719
- Testing
- Duloxetine hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 258 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathies, Pain
Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT00283842
- Testing
- DVS SR
- Where
- 51 sites in United States
- Volunteers
- 408 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.
- Trial name
- NCT04688671
- Testing
- ETX-018810
- Where
- 22 sites in United States
- Volunteers
- 167 people
- Sponsor
- Eliem Therapeutics (UK) Ltd.
Diabetic Peripheral Neuropathic Pain
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain
This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of diabetic peripheral neuropathic pain.
- Trial name
- NCT04707157
- Testing
- LY3556050
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Diabetic Peripheral Neuropathy
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the safety, tolerability and effectiveness of DS-5565 compared to placebo (inactive substance) and pregabalin in diabetic subjects with DPN.
- Trial name
- NCT01496365
- Testing
- DS-5565 tablet, pregabalin capsule
- Where
- 78 sites in United States
- Volunteers
- 452 people
- Sponsor
- Daiichi Sankyo
Pain, Diabetic Peripheral Neuropathy
Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to investigate the effectiveness and safety of DS-5565, compared to placebo, in subjects with pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT01504412
- Testing
- DS-5565, Pregabalin capsules
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 450 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Neuropathic Pain
Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain
Based on laboratory studies, donepezil will improve pain relief more than placebo in patients with chronic neuropathic pain who are currently taking gabapentin or pregabalin.
- Trial name
- NCT01743976
- Testing
- Donepezil
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University
Painful Diabetic Neuropathy
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Diabetic Neuropathic Pain (DNP) over a 15 week treatment phase.
- Trial name
- NCT01129960
- Testing
- Eslicarbazepine acetate (BIA 2-093)
- Where
- Portugal
- Volunteers
- 332 people
- Sponsor
- Bial - Portela C S.A.
Diabetic Peripheral Neuropathy
Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain
The purpose of this study is to determine whether low level laser therapy is effective in the reduction of foot pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT02461225
- Testing
- Erchonia® FX-635™
- Where
- 2 sites in United States, Ireland
- Volunteers
- 30 people
- Sponsor
- Erchonia Corporation
Diabetic Neuropathy, Painful
A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
The purpose of this study is to test whether a new treatment will be safe and effective in treating pain. Patients with diabetic peripheral neuropathy will be included.
- Trial name
- NCT00785577
- Testing
- Pregabalin, LY545694 21 mg, LY545694 49 mg
- Where
- 13 sites in United States, Mexico and 1 more
- Volunteers
- 273 people
- Sponsor
- Eli Lilly and Company
Diabetic Peripheral Neuropathy, Pain
A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
The purpose of the study is to assess efficacy and safety of a single treatment of Capsaicin 8% transdermal delivery system in reducing pain from damaged nerves (neuropathic pain) caused by diabetes.
- Trial name
- STEP (NCT01533428)
- Testing
- Capsaicin 8%
- Where
- 29 sites in United States
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Pain
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic…
- Trial name
- NEPTUNE-17 (NCT05838755)
- Testing
- GSK3858279
- Where
- 81 sites in United States, Canada and 9 more
- Volunteers
- 147 people
- Sponsor
- GlaxoSmithKline
Diabetic Peripheral Neuropathy, Diabetes
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing pain related to diabetic peripheral neuropathy (DPNP) over an 11 week assessment period.
- Trial name
- RELIEF-DPN 1 (NCT04455633)
- Testing
- LX9211
- Where
- 44 sites in United States
- Volunteers
- 319 people
- Sponsor
- Lexicon Pharmaceuticals
Chronic Pain, Diabetic Neuropathies
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing…
- Conditions
- Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
- Trial name
- NCT01939366
- Testing
- Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg
- Where
- 82 sites in United States, Austria and 6 more
- Volunteers
- 699 people
- Sponsor
- Tris Pharma, Inc.
Idiopathic Peripheral Neuropathy
A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
This is an 11-week randomized, double-blind, placebo-controlled trial of Milnacipran 100 mg/d in patients with idiopathic neuropathic pain.
- Trial name
- NCT01288937
- Testing
- Milnacipran
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Diabetic Peripheral Neuropathy, Neuralgia
A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy
This is a multicenter, randomized, placebo-controlled, parallel group study of EpiCept™ NP-1 Topical Cream (amitriptyline 4%/ketamine 2%) in approximately 200 patients with pain in the lower extremities due to diabetic nerve pain.
- Trial name
- NCT00476151
- Testing
- EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream
- Where
- India
- Volunteers
- 226 people
- Sponsor
- EpiCept Corporation
Diabetic Neuropathies, Neuralgia
Pregabalin Peripheral Neuropathic Pain Study
To evaluate the efficacy of pregabalin, using a flexible, optimized dose schedule with dose adjustment based on Daily Pain Rating Scale (DPRS), compared to placebo in subjects with peripheral neuropathic pain.
- Trial name
- NCT00141219
- Testing
- pregabalin
- Where
- 10 sites in South Korea
- Volunteers
- 241 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Peripheral Neuropathic Pain
A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain
This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of RTA 901 in qualified participants with Diabetic Peripheral Neuropathic…
- Trial name
- CYPRESS (NCT05895552)
- Testing
- RTA 901
- Where
- 75 sites in United States
- Volunteers
- 209 people
- Sponsor
- Reata, a wholly owned subsidiary of Biogen